Inspra

Eplerenone, the active ingredient in Inspra, is an aldosterone antagonist presented as an oral tablet for oral use. It blocks the mineralocorticoid receptor, reducing sodium retention and potassium loss, which helps lower blood pressure and mitigate cardiac remodeling. The medication is indicated for the treatment of hypertension, heart failure, and for patients after myocardial infarction, primarily in adult populations.

GNH USA supplies Inspra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution for global healthcare providers.

Eplerenone (Inspra) acts on the mineralocorticoid pathway to manage several cardiovascular conditions. - Hypertension: reduces elevated blood pressure by blocking aldosterone‑induced sodium and water retention, improving vascular tone in patients with primary hypertension. - Heart failure: decreases mortality and hospitalization rates by attenuating aldosterone‑driven cardiac remodeling and fluid overload in patients with reduced‑ejection‑fraction heart failure. - Post‑myocardial infarction: mitigates adverse ventricular remodeling and lowers the risk of subsequent cardiovascular events when initiated after an acute myocardial infarction.

Eplerenone may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Hyperkalemia: elevated serum potassium levels. - Hyponatremia: low sodium concentration in blood. - Dizziness or light‑headedness, especially on standing. - Headache.

Serious or Rare Side Effects: - Severe hyperkalemia leading to cardiac arrhythmia. - Acute kidney injury or worsening renal function. - Allergic reactions such as rash, pruritus, or angioedema.

When prescribing Eplerenone, clinicians should consider several precautionary measures to ensure patient safety. - Renal function: assess baseline kidney function and monitor regularly, especially in patients with chronic kidney disease. - Serum potassium: check potassium levels before initiation and periodically during therapy. - Concomitant potassium‑sparing drugs: avoid or use with caution to prevent hyperkalemia. - Pregnancy: category B; use only if potential benefit justifies potential risk to the fetus. - Drug interactions: review patient’s medication list for agents that affect potassium or renal function. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Eplerenone interacts with several medicines; understanding the interaction level guides clinical decisions.

Major Interactions (Avoid): - ACE inhibitors or ARBs combined with high potassium supplements: risk of severe hyperkalemia. - Potassium‑rich salt substitutes: may cause dangerous potassium accumulation. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase eplerenone plasma concentrations.

Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen, naproxen): can impair renal function and elevate potassium. - Diuretics that spare potassium (e.g., spironolactone, amiloride): may enhance hyperkalemia risk. - Digoxin: altered serum potassium may affect digoxin toxicity.